1. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
- Author
-
Jia Q, Jia C, Liu Y, Yang Y, Qi J, Tong L, Chen H, Zhang M, Che J, Li B, and Li Z
- Subjects
- Adolescent, Adult, Africa, Age Factors, Asian People, China, Female, Humans, Male, Middle Aged, Military Personnel, Time Factors, Vaccines, Attenuated immunology, Vaccines, Attenuated therapeutic use, Yellow Fever blood, Yellow Fever immunology, Yellow Fever Vaccine immunology, Yellow fever virus, Young Adult, Antibodies, Viral blood, Immunogenicity, Vaccine, Yellow Fever prevention & control, Yellow Fever Vaccine therapeutic use
- Abstract
Yellow fever is a serious disease caused by infection with the yellow fever virus (YFV). A live-attenuated YFV vaccine strain, 17D (YFV-17D) is the only virus strain available for the production of the YFV vaccine. This study evaluated the immunogenicity and immune persistence of vaccination with YFV-17D and identified their influencing factors in Chinese peacekeepers deployed to Africa. Serum specimens were collected before and ≥21 days after primary vaccination with YFV-17D in 349 Chinese peacekeepers who were subsequently deployed to Africa for the first time from 2016 to 2017 (population 1). Serum specimens were collected from 1 to 11 years after vaccination with YFV-17D in 2062 returned Chinese peacekeepers who were deployed to Africa from 2005 to 2015 (population 2). We found that YFV-17D exhibited an excellent protective effect in the Chinese peacekeepers deployed to Africa early following vaccination. In the Chinese peacekeepers one year after vaccination, the serum antibody titer against YFV increased with increasing age at vaccination; in those two or more years after vaccination, the serum antibody titer against YFV decreased over years and was similar to but greater than the minimum protective level 11 years after vaccination. The number of peacekeeping missions exhibited an almost negligible influence on the serum antibody titer against YFV. (This study has been registered at International Clinical Trials Registry Platform (http://www.who.int/ictrp/en/) under registration Nos. ChiCTR1800017024.)., (Copyright © 2018. Published by Elsevier B.V.)
- Published
- 2019
- Full Text
- View/download PDF